RxDoctor Payments Data

Melenda Miller, MD

Family Medicine · Glasgow, KYNPI 1083886568

Payments from drug & device makers

$785in general payments, 2019–2025

Across 48 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$277
  • AbbVie$103
  • AstraZeneca$88
  • Amgen$69
  • Amarin Pharma, Inc.$68
  • Merck$57
  • plus $124 from 5 others

What the payments were for

  • Food & beverage$78099%
  • Education$51%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson17$277
AbbVie(2 entities)6$103
AstraZeneca6$88
Amgen3$69
Amarin Pharma, Inc.4$68
Merck4$57
Novo Nordisk3$41
Boehringer Ingelheim2$37
Novartis1$16
GSK1$16
Pfizer1$14

How this compares

$785 in reported general payments places this provider in the 50th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$58,791
Medicare patients
202
Services billed
634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol146$139,096
JanuviaSitagliptin Phosphate160$133,627
JardianceEmpagliflozin107$111,530
OzempicSemaglutide96$102,553
EliquisApixaban25$31,546
LinzessLinaclotide37$25,291
XareltoRivaroxaban14$20,930
Combivent RespimatIpratropium/Albuterol Sulfate22$16,583
RexultiBrexpiprazole11$15,651
Breo ElliptaFluticasone/Vilanterol24$15,311
MounjaroTirzepatide14$14,073
Ondansetron Hcl51$12,574
InvokanaCanagliflozin12$12,322
Lantus SolostarInsulin Glargine,hum.Rec.Anlog94$11,372
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$11,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$88$139,096146 claims
Boehringer IngelheimJardiance, Combivent Respimat, Jentadueto Xr$37$134,168141 claims
MerckJanuvia$57$133,627160 claims
Novo NordiskOzempic$41$102,55396 claims
Johnson & JohnsonXarelto, Invokana$277$33,25226 claims
PfizerEliquis$14$31,54625 claims
AbbVieLinzess, Synthroid$103$28,11276 claims
GSKBreo Ellipta, Anoro Ellipta$16$26,53448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Glasgow

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →